About

Xeris is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke ®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis ®, a proven therapy for primary periodic paralysis; and Recorlev ® for the treatment of endogenous Cushing’s syndrome. Xeris has a diverse pipeline of development and partnered programs using its formulation sciences, XeriSol™ and XeriJect ®, to support long-term product development and commercial success. Xeris Biopharma Holdings is headquartered in Chicago, IL.